Amarantus partners with US Army Institute to develop treatment for severe wound conditions
Amarantus BioScience (OTCQX: AMBS) on Monday said it has partnered with the US Army Institute of Surgical Research (USAISR) and Rutgers to collaborate on developing a treatment of deep burn wounds in adults.
The biotechnology company is set to start Phase II clinical trials for its full thickness skin replacement product, Engineered Skin Substitute (ESS), in the third quarter of 2015. ESS has received orphan drug designation from the US Food and Drug Administration for the treatment of hospitalized patients with deep partial and full thickness burns requiring grafting.
Amarantus has signed a Cooperative Research and Development Agreement (CRADA) with the US Army Institute of Surgical Research (USAISR) and Rutgers, The State University of New Jersey (Rutgers University).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze